Skip to main content
Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
7.28
-0.55 (-7.02%)
At close: Feb 21, 2025, 4:00 PM
7.38
+0.10 (1.37%)
After-hours: Feb 21, 2025, 5:41 PM EST

Verve Therapeutics Revenue

Verve Therapeutics had revenue of $6.87M in the quarter ending September 30, 2024, with 120.24% growth. This brings the company's revenue in the last twelve months to $24.40M, up 219.91% year-over-year. In the year 2023, Verve Therapeutics had annual revenue of $11.76M with 505.77% growth.

Revenue (ttm)
$24.40M
Revenue Growth
+219.91%
P/S Ratio
24.00
Revenue / Employee
$95,671
Employees
255
Market Cap
616.35M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202311.76M9.82M505.77%
Dec 31, 20221.94M--
Dec 31, 2021---
Dec 31, 2020---
Dec 31, 2019---
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 400.28B
Johnson & Johnson 88.82B
Merck & Co. 64.17B
AbbVie 56.33B
AstraZeneca 54.07B
Novartis AG 51.72B
Eli Lilly and Company 45.04B
Thermo Fisher Scientific 42.88B
Revenue Rankings

VERV News

More News